ReviewCureus2023
A Review of Artificial Intelligence-Based Gait Evaluation and Rehabilitation in Parkinson's Disease.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Knowledge mapping and research trends of accidental falls in patients with Parkinson's disease from 2003 to 2023: a bibliometric analysis.Frontiers in neurology · 2024Pooled it
- Using explainable AI to identify disease-relevant and deep brain stimulation treatment-sensitive gait features in Parkinson's disease.Journal of neuroengineering and rehabilitation · 2026Article
- 80N as the Optimal Assistive Threshold for Wearable Exoskeleton-Mediated Gait Rehabilitation in Parkinson's Disease: A Prospective Biomarker Validation Study.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a long-term degenerative disease of the central nervous system that affects both motor and non-motor functions. In most cases, symptoms develop gradually, with non-motor symptoms increasing in frequency as the condition progresses. Tremors, stiffness, slow movements, and difficulty walking are some of the early symptoms. There may be problems with cognition, behavior, sleep, and thinking. Dementia caused by PD becomes more common as the disease progresses. The development of PD is linked to certain sequences of motion that eventually contribute to diminished function. Patients with Parkinson's disease (PWPD) have a sluggish, scattered gait that is accompanied by intermittent freezing of gait (FOG), in which efficient heading briefly pauses. In individuals with severe PD, FOG is a neurological deficit that is related to falls and has an unfavorable impact on the patient's standard of living. Artificial intelligence (AI) and ambient intelligence (AmI) are inextricably linked as intelligence is the ability to gain new information and employ it in novel contexts. The ambience is what accompanies us, while artificial represents something developed by humans. Wearable technologies are being designed to recognize FOG and support patients in the beginning to walk again via periodic cueing. The article proposes a unique automated approach for action description that utilizes AI to carry out a non-intrusive, markerless evaluation in real-time and with full robotics. This computerized method accelerates detection and safeguards from human error. Despite significant improvements brought about by the advent of novel technologies, the available assessment platforms still fail to strike the ideal equilibrium among expenditure, diagnostic precision, velocity, and simplicity. The value of the recommended approach can be seen through a comparison of the gait parameters collected by each of the motion-tracking gadgets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.